NEW DELHI: The Indian Pharmacopoeia Commission (IPC) has signed a Memorandum of Understanding (MoU) with the Uttar Pradesh Promote Pharma Council (UPPPC) to strengthen quality standards, regulatory compliance and innovation in the pharmaceutical and medical device sectors, it was announced on Wednesday.
The Ministry of Health and Family Welfare said that the agreement was signed during the YEIDA MedTech Investors Meet and Site Visit 2026, held at the India Expo Mart.
The strategic partnership aims to strengthen the pharmaceutical and medical device ecosystem by promoting quality standards, regulatory excellence, innovation and capacity building across the sector, according to the ministry.
Under the pact, IPC and UPPPC will work together to strengthen quality standards and regulatory compliance in the pharmaceutical and medical device industries while promoting awareness of the Indian Pharmacopoeia, pharmacovigilance and materiovigilance.
In addition, the two organisations will organise joint training programmes, workshops and stakeholder awareness initiatives to enhance industry capabilities.
The partnership will focus on fostering research, innovation and industry-academia collaborations, while supporting micro, small and medium enterprises (MSMEs) through digital tools for adverse event reporting.
The MoU also aims to enhance patient safety by strengthening quality assurance and post-market surveillance mechanisms, the ministry said.
It further noted that the collaboration reflects IPC's continued commitment to advancing high-quality healthcare standards, supporting innovation and strengthening India's regulatory framework.
The initiative is also expected to contribute to the growth of Uttar Pradesh as a leading hub for pharmaceuticals, medical devices and healthcare technologies.
According to the ministry, the partnership seeks to build a stronger ecosystem that promotes quality, safety, innovation and global competitiveness in the pharmaceutical and medical technology sectors.
Earlier in April, the IPC signed two MoUs with government institutes to strengthen quality assurance, ensure rational use of medicines, pharmacovigilance and collaborative research.
--IANS
